Pipemidic acid, a structural relative of piromidic and nalidixic acids, exhibited substantial therapeutic activity when it was administered orally to mice bearing either widely disseminated or relatively localized infections with Staphylococcus aureus and a variety of gram-negative bacilli. The activity of pipemidic acid was always greater than that of piromidic and nalidixic acids; in infections with Pseudomonas aeruginosa and in bacilli resistant to the latter two drugs, pipemidic acid exhibited significant activity. In limited comparative studies, the activities of pipemidic acid were generally superior to the activities of cephalexin, ampicillin, and carbenicillin. Gentamicin, administered subcutaneously, was more active than pipemidic acid, given either orally or subcutaneously, against both systemic and localized infections with P. aeruginosa. The therapeutic accomplishments of pipemidic acid were attained with well-tolerated doses. (3) is a new antibacterial agent related structurally to piromidic and nalidixic acids (1, 5). Previous reports (6, 7) have dealt with the in vitro activity of pipemidic acid against a wide range of gram-positive and gram-negative bacteria and with the absorption, tissue distribution, excretion, metabolic fate, and toxicity of this agent as exhibited in mice, rats, dogs, rhesus monkeys, and humans. The current report summarizes the results of a group of studies concerned with the effectiveness of pipemidic acid in treating experimentally induced systemic and more or less localized infections in mice. The design of the studies made possible a limited comparison of the activities of pipemidic acid with those of piromidic and nalidixic acids, cephalexin, ampicillin, gentamicin, and carbenicillin.
Pipemidic acid [8-cthyl-5,8-dihydro-5-oxo-2-(1 -piperazinyl) -pyrido(2,3-d)pyrimidine -6-carboxylic acid] (3) is a new antibacterial agent related structurally to piromidic and nalidixic acids (1, 5) . Previous reports (6, 7) have dealt with the in vitro activity of pipemidic acid against a wide range of gram-positive and gram-negative bacteria and with the absorption, tissue distribution, excretion, metabolic fate, and toxicity of this agent as exhibited in mice, rats, dogs, rhesus monkeys, and humans. The current report summarizes the results of a group of studies concerned with the effectiveness of pipemidic acid in treating experimentally induced systemic and more or less localized infections in mice. The design of the studies made possible a limited comparison of the activities of pipemidic acid with those of piromidic and nalidixic acids, cephalexin, ampicillin, gentamicin, and carbenicillin.
MATERIALS AND METHODS Drugs. Pipemidic acid trihydrate was synthesized in this laboratory (3) , and its dose or concentration was always expressed as that of anhydrous compound. Piromidic and nalidixic acids were prepared as described previously (5). Cephalexin and gentamicin sulfate were obtained from Shionogi Co., Ltd., sodium carbenicillin was from Fujisawa Pharmaceutical Co., Ltd., and ampicillin was from Meiji Seika Kaisha, Ltd. These compounds were dissolved in water for the in vitro study or for subcutaneous injection, and they were suspended in 0.2% carboxymethyl cellulose for oral administration. Sodium hydroxide was added for the dissolution of pipemidic, piromidic, and nalidixic acids in water.
Organisms. The following stock organisms were utilized in the various therapeutic assessments: Staphylococcus aureus 50774, Escherichia coli P-5101, Klebsiella pneumoniae 13, Proteus morganii Kono, Pseudomonas aeruginosa 12, and Salmonella typhimurium S-9. In addition, three freshly isolated organisms (E. coli P-174, P. mirabilis P-287, and P. aeruginosa Ky-44), all highly resistant in vitro to piromidic and nalidixic acids, were included in the evaluations.
Assessments of in vitro activity. Measurements of the in vitro activities of pipemidic acid and other agents were limited to the test organisms listed above. These assessments were carried out by an agar dilution procedure described in detail elsewhere (7) .
Assessments of therapeutic activity. The therapeutic potentials of pipemidic acid were explored in four model infections, each induced in groups of 10 or more ddy-s mice weighing 20 + 2 g. A comparison of drug efficacy was made on the basis of the mean effective dose (ED50) calculated by probit analysis (4), and a 95% confidence limit that was calculated by the method of Litchfield and Wilcoxon (2).
(i) Systemic infections. Systemic infections were produced by inoculating male mice intravenously (S. aureus) or intraperitoneally (the other strains) with the following test strains suspended in 0.4 ml of menstruums: S. aureus 50774, 5 x 101 cells in 0.8% saline;E. coli P-5101, 9 x 101 cells, E. coli P-174, 6 (ii) Urinary bladder-kidney infections. Urinary bladder-kidney infections were induced in female mice by instilling the following test strains directly into the exposed bladders of mice lightly anesthetized with sodium pentobarbital: E. coli P-5101, 1 Mice were sacrificed 5 days after inoculation. Kidneys were removed aseptically and bisected, and the two halves were pressed on an agar plate containing an appropriate medium. The agars employed were Staphylococcus medium no. 110 (Nissan) for S. aureus, MacConkey agar (Nissan) for E. coli and K. pneumoniae, and King medium A (Nissan) for P. aeruginosa. The absence of growth on the agar surface after 20 h of incubation at 37 C was the sole end point of therapeutic achievement.
(iii) Pulmonary infections. Female mice were inoculated intranasally with 2 x 107 P. aeruginosa 12, suspended in 0.05 ml of 0.8% saline. Pipemidic acid and other therapeutic agents were administered immediately after inoculation and 1 and 3 h thereafter. Survival 5 days after challenge was used as the end point for therapeutic efficacy.
(iv) Dermal infections. Female mice were inoculated subcutaneously in a depilated area of the back with 9 x 106P. aeruginosa 12, suspended in 0.2 ml of 0.8% saline. Therapeutic agents were administered immediately after inoculation and 3, 6, 24, 27, and 30 h later. The absence of skin abscesses 4 days after inoculation was employed as the indicator of therapeutic accomplishment. RESULTS
In vitro activities of various therapeutic agents against organisms used in model infections. The results of the in vitro susceptibility studies, summarized in Table 1 , show that there was a relatively small variation, from 3.13 to 25 ,ug per ml of medium, in the concentration of pipemidic acid required to inhibit the growth of the various test organisms. In absolute terms, the range of minimal inhibitory concentrations was much greater for piromidic and nalidixic acids, from 12.5 to >400 ug per ml for the former compound and from 3.13 to >400
,ug per ml for the latter. Except for the activity of piromidic acid against S. aureus 50774 and the activity of nalidixic acid against E. coli P-5101 and S. typhimurium S-9, pipemidic acid was substantially more effective than these agents. Table 2 . There was a 20-fold variation in the doses of pipemidic acid required to achieve the same level of protection against systemic infections with the various test organisms. The data in Table 2 also show there is a reasonably good correlation between the relative activity of pipemidic acid against systemic infections with the various test organisms and relative in vitro activity.
Data on the activities of pipemidic acid against urinary bladder-kidney, pulmonary, and dermal infections are limited. In urinary bladder-kidney infections, the ED50 values for gram-negative bacilli showed a tendency to be small, as compared with the corresponding systemic infections. There was a 6-fold variation in the ED50 values of this agent for the various infection models of P. aeruginosa 12.
Comparative activites of pipemidic, piromidic, and nalidixic acids, and cephalexin and ampicillin against systemic and urinary bladder-kidney infections. The data summarized in Table 3 show that, dose for dose, pipemidic acid was uniformly more effective than piromidic and nalidixic acids in both the systemic and urinary bladder-kidney infection models. The relative positions of pipemidic acid, cephalexin, and ampicillin varied, depending upon both test organism and experimental model. Cephalexin and ampicillin were clearly more effective than pipemidic acid against infections with S. aureus 50774, but they were definitely less effective against infections with gram-negative bacilli, with one exception each.
Comparative activities of pipemidic acid, carbenicillin, and gentamicin against various experimental infections with P. aeruginosa. Table 4 summarizes the results of a limited comparison of the activities of pipemidic acid, carbenicillin, and gentamicin, administered subcutaneously, against various types of infections with P. aeruginosa. The activities of pipemidic acid given orally are included for comparison. This summary shows that, dose for dose, pipemidic acid given orally or subcutaneously is more active than carbenicillin and less active than gentamicin in each of the model systems in which P. aeruginosa 12 was used as the infecting organism. The superiority of gentamicin was lost in systemic infections with the Ky-44 strain, where it was impossible to achieve 50% protection with eight times the dose that gave such a result when mice were infected with strain 12. In contrast, the dose of pipemidic acid required for protection against strain Ky-44 was less than twice that required for strain 12. Activity of pipemidic acid against systemic infections with piromidic and nalidixic acid-resistant strains ofE. coli and P. mirabiUis. As shown in Table 5 , pipemidic acid provided significant levels of protection against infections with the P-174 strain ofE. coli and P-287 strain of P. mirabilis at doses of 204.1 and 72.3 mg/kg, respectively. Piromidic acid at a dose of 800.0 mg/kg and nalidixic acid at a dose of 400.0 mg/kg were ineffective. Comparison of the activities of pipemidic acid referred to above with those exhibited against the P-5101 strain of E. coli shows that the effectiveness of this agent was reduced significantly in the face of resistance to piromidic and nalidixic acids. However, this reduction was not so great as to eliminate the therapeutic potential of pipemidic acid.
DISCUSSION
Since several of the models of infections employed in assessing the therapeutic activities of pipemidic acid are not in common use, a few comments on the major features of these models as exhibited in untreated mice are indicated. Systemic infections, induced by either intraperitoneal or intravenous inoculation of S. aureus and various gram-negative bacilli, are usually lethal within 96 h. Survival rates 1 or 2 weeks after challenge rarely exceed 10%. In the more localized urinary bladder-kidney infections, untreated mice invariably exhibited renal enlargement with multiple foci of necrosis 5 days after inoculation. At that time, from 105 to 108 colony-forming units of the infecting organism could be recovered from the kidneys of each untreated mouse; heart blood, liver, lung, and spleen were uniformly culture negative. Pulmonary infections, induced by intranasal instillation of P. aeruginosa, were rapidly lethal in untreated mice. Some animals died within 6 h of inoculation; all were dead within 24 h. Death was usually associated with extensive pulmonary hemorrhage. Intradermal infections evoked by inoculation with P. aeruginosa developed rapidly in untreated mice, with abscess formation 2 days after challenge and focal areas of necrosis, measuring up to 20 mm in diameter, at 4 days. Despite this early fulminating course, these dermal lesions regressed spontaneously and gradually healed.
The evolution of the various lesions encountered in untreated mice suggests that the spectrum of models utilized in this study presents a gradation of challenges to any therapeutic agent, ranging from moderate to severe. Under such challenges, pipemidic acid proved to be effective in oral doses that were a small fraction of the maximum tolerated dose (6) . Compared with other oral chemotherapeutics, the accomplishments of pipemidic acid were clearly superior to those of piromidic and nalidixic acids and, as concerns gram-negative bacilli, generally exceeded those of cephalexin and ampicillin. As for infections with P. aeruginosa, the accomplishments of pipemidic acid given orally or subcutaneously were invariably superior to those of carbenicillin but evidently inferior to gentamicin, both administered subcutaneously. This result is noteworthy because there are at present only a few drugs clinically available for P. aeruginosa infections by the oral route. Another interesting property of this agent is its activity against infections due to bacilli resistant to piromidic and nalidixic acids. Incomplete cross-resistance between pipemidic acid and the structural relatives observed in vitro (7) was, thus, true in the experimental infections. Such a relatively favorable in vivo effect of pipemidic acid seems to reflect its pharmacological and metabolic properties (6) .
It must be recognized, however, that the studies described in this report constitute no more than a limited assessment of the in vivo activity of pipemidic acid. Experiments on delayed therapy, where medication begins after infections are better established, and on longterm survival rates and total eradication of infectious agents may be necessary for full assessments of this agent.
Clinical evaluation is necessary to determine the position of pipemidic acid among available chemotherapeutic agents.
